MSParis 2017 Poster Gallery

 

7th Joint ECTRIMS-ACTRIMS meeting, Paris, France, October 25-28, 2017
Selected posters presented by researchers at MSParis 2017.

Dr. Bruce Cree: Confirmed Disability Improvement in Patients Treated with Fingolimod in Phase 3 and Extension Trial Programmes for up to 96 Months

Dr. Per Soelberg-Sorensen: Long-Term Lymphocyte Counts in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets 3.5 mg/kg: Total Lymphocytes, B and T Cell Subsets

Dr. Tjalf Ziemssen: Effect of Early Switch to Fingolimod From Other Oral Therapies in Patients With Relapsing–Remitting Multiple Sclerosis

Heather Yong: An Observational Study of Alemtuzumab treated Relapsing MS Patients at the UBC MS Clinic

Confirmed Disability Improvement in Patients Treated with Fingolimod in Phase 3 and Extension Trial Programmes for up to 96 Months (Poster 672). Authors: Bruce A. C. Cree, Jeffrey Cohen, Diego Silva, Shannon Ritter, Daniela Piani Meier, Davorka Tomic, David Leppert, Ludwig Kappos
Discussant: Dr. Bruce Cree

Long-Term Lymphocyte Counts in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets 3.5 mg/kg: Total Lymphocytes, B and T Cell Subsets (Poster P655). Authors: P. Soelberg-Sorensen, F. Dangond, C. Hicking, G. Giovannoni
Discussant: Dr. Per Soelberg-Sorensen

 

Effect of Early Switch to Fingolimod From Other Oral Therapies in Patients With Relapsing–Remitting Multiple Sclerosis (Poster P790). Authors: Tjalf Ziemssen, Diego Silva, Jennie Medin, Christian Cornelissen, Kathrin Ringwald, Stanley Cohan
Discussant: Dr. Tjalf Ziemssen

An Observational Study of Alemtuzumab treated Relapsing MS Patients at the UBC MS Clinic (Poster P681). Authors: H. Yong, P. Beauchemin, K. Barclay, V. Devonshire, A. Sayao, R. Carruthers, A.Traboulsee
Discussant: Heather Yong

 

Recommend to a Colleague

Related Posts

Go back to home page